The following Structured Product Label (SPL) was submitted to the FDA by Apotheca Inc. for the product Meclizine Hydrochloride (NDC 12634-424). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding description, clinical pharmacology, pharmacokinetics, absorption, distribution, metabolism, elimination, contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Chemically, meclizine hydrochloride is 1-( p-chloro-α-phenylbenzyl)-4-( m-methylbenzyl) piperazine dihydrochloride monohydrate.
Chemical Structure (Image 01)
C 25H 27CIN 2·2HCl·H 20 M.W. 481.89
Meclizine hydrochloride tablets, USP are available in two different strengths, 12.5 mg and 25 mg. Inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The 12.5 mg tablet also contains FD&C Blue #1 Aluminum Lake.
Meclizine hydrochloride is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.
The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.
Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.
Drug distribution characteristics for meclizine in humans are unknown.
The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP 2D6 was found to be the dominant enzyme for metabolism of meclizine.
The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.
Meclizine has a plasma elimination half-life of about 5-6 hours in humans.
Meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.
Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.
Patients should avoid alcoholic beverages while taking this drug.
Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.
Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.
Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.
The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.
The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.
There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers, and sedatives. (see WARNINGS)
Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.
Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.
The initial dose of 25 to 50 mg of meclizine hydrochloride should be taken one hour prior to embarkation for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
25 mg, white, modified oval-shaped tablets, de-bossed “ Є14” on one side and plain on the other side. They are supplied as follows:
NDC 12634-424-00 Bottles of 10
NDC 12634-424-01 Bottles of 100
NDC 12634-424-09 Bottles of 35
NDC 12634-424-12 Bottles of 120
NDC 12634-424-18 Bottles of 180
NDC 12634-424-40 Bottles of 40
NDC 12634-424-42 Bottles of 42
NDC 12634-424-45 Bottles of 45
NDC 12634-424-50 Bottles of 50
NDC 12634-424-52 Blister Pack of 12
NDC 12634-424-54 Blister Pack of 14
NDC 12634-424-57 Blister Pack of 20
NDC 12634-424-59 Blister Pack of 30
NDC 12634-424-60 Bottles of 60
NDC 12634-424-61 Blister Pack of 10
NDC 12634-424-63 Blister Pack of 3
NDC 12634-424-66 Blister Pack of 6
NDC 12634-424-67 Blister Pack of 7
NDC 12634-424-69 Blister Pack of 9
NDC 12634-424-71 Bottles of 30
NDC 12634-424-74 Bottles of 24
NDC 12634-424-78 Bottles of 28
NDC 12634-424-79 Bottles of 25
NDC 12634-424-80 Bottles of 20
NDC 12634-424-81 Bottles of 21
NDC 12634-424-82 Bottles of 12
NDC 12634-424-84 Bottles of 14
NDC 12634-424-85 Bottles of 15
NDC 12634-424-90 Bottles of 90
NDC 12634-424-91 Blister Pack of 1
NDC 12634-424-92 Bottles of 2
NDC 12634-424-93 Bottles of 3
NDC 12634-424-94 Bottles of 4
NDC 12634-424-95 Bottles of 5
NDC 12634-424-96 Bottles of 6
NDC 12634-424-97 Bottles of 7
NDC 12634-424-98 Bottles of 8
NDC 12634-424-99 Bottles of 9
Store at 20° to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required.
Manufactured by:
Epic Pharma, LLC
Laurelton, NY 11413
Manufactured in USA
Revised January 2016
MF012REV01/16
OE1035
Repackaged & Distributed by:
Apotheca Inc.
Phoenix, AZ 85006
Meclizine Hydrochloride Tablets USP, 25 mg
25 mg
Rx Only
30 Tablets
Label (424 71)
* Please review the disclaimer below.
